Loading clinical trials...
Loading clinical trials...
An Open-Label, Long-Term Study to Assess the Safety and Efficacy of AXS-07 (MoSEIC™ Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults
Conditions
Interventions
AXS-07
Locations
51
United States
Clinical Research Site
Birmingham, Alabama, United States
Clinical Research Site
Birmingham, Alabama, United States
Clinical Research Site
Mobile, Alabama, United States
Clinical Research Site
Phoenix, Arizona, United States
Clinical Research Site
Canoga Park, California, United States
Clinical Research Site
Colton, California, United States
Start Date
July 6, 2019
Primary Completion Date
September 22, 2020
Completion Date
September 22, 2020
Last Updated
October 10, 2023
NCT07018713
NCT06641466
NCT04715685
NCT07476053
NCT05734625
NCT06616194
Lead Sponsor
Axsome Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions